Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species

  • Fernández-Bastit, Leira|||0000-0002-7766-939X
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Blanco, Julià|||0000-0002-2225-0217
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the coronavirus disease 19 (COVID-19) pandemic, significantly impacting global health, economies, and social stability. In February 2020, the first cases of SARS-CoV-2 infections in animals were documented, highlighting the potential risks posed by regular human-animal interactions in facilitating viral transmission. In consequence, it is essential to validate surveillance methods for SARS-CoV-2 in animals. In the present study, 101 sera from different animal species (36 cats, 41 dogs, 4 ferrets, 10 wild boar, 6 domestic goats, and 4 lions) were tested using three different ELISA kits to evaluate humoral responses against SARS-CoV-2. ELISA results were compared and correlated with a pseudovirus neutralization test (pVNT), considered as the reference assay. ELISA-1, targeting the receptor binding domain (RBD) neutralizing antibodies (nAbs) of SARS-CoV-2, exhibited the highest diagnostic performance, and proved to be a reliable tool for initial screenings in high-throughput animal studies. In contrast, ELISA-2 (also targeting RBD nAbs) and ELISA-3 (targeting nucleoprotein antibodies) demonstrated lower sensitivity for detecting seropositive animals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model

  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Pérez, Mònica
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Tondelli, Barbara
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Capdevila, Sara
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Urrea, Víctor|||0000-0002-2577-856X
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Ballana, Ester|||0000-0002-5215-7363
  • Forrow, Stephen
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Blanco, Julià|||0000-0002-2225-0217
K18-hACE2 mice express high levels of the human protein angiotensin-converting enzyme 2 (ACE2), the receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and are therefore susceptible to infection by this virus. These animals have been crucial to understanding viral pathogenesis and to testing coronavirus disease 2019 (COVID-19) vaccines and antiviral drugs. However, K18-hACE2 often dies after infection with initial SARS-CoV-2 variants, likely due to a massive brain infection that does not occur in humans. Here, we used a technology known as knock-in (KI) that allows for the targeted insertion of a gene into a mouse, and we have generated a new human ACE2 (hACE2) mouse. We have characterized this new animal model demonstrating that, upon challenge with SARS-CoV-2, the virus replicates in the respiratory tract, damaging lung tissue and causing inflammation. In contrast to K18-hACE2 mice, only limited or no brain infection could be detected in this new model. After 14 days, most animals recovered from the infection, although lung tissue lesions were still observed. This new model could be instrumental for the study of specific disease aspects such as post-COVID-19 condition, sequelae, and susceptibility to reinfection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immune Durability and Breakthrough Infections 15 Months After SARS-CoV-2 Boosters in People over 65, The IMMERSION Study

  • Violán, Concepció|||0000-0003-3309-5360
  • Quirant, Bibiana|||0000-0002-3875-8074
  • Palau Antoja, Maria|||0009-0003-4552-6268
  • Palacin, Dolors
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Trigueros Peña, Macedonia|||0000-0003-4156-1018
  • Pera, Guillem|||0000-0003-3188-7268
  • Molist, Gemma|||0000-0002-0927-1945
  • Fernandez Rivas, Gema|||0000-0003-4854-5934
  • Boigués, Marc
  • Isnard, Mar|||0000-0001-6297-8520
  • Prat Gil, Nuria|||0000-0003-1689-9017
  • Carmona Cervelló, Meritxell|||0000-0003-0907-9168
  • Lamonja-Vicente, Noemí|||0000-0003-1342-1130
  • León-Gómez, Brenda Biaani|||0000-0001-5327-4409
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Blanco, Julià|||0000-0002-2225-0217
  • Massanella, Marta|||0000-0002-3326-151X
  • Torán-Monserrat, Pere|||0000-0002-9865-7427
Background : SARS-CoV-2 booster vaccination remains essential to prevent severe COVID-19, particularly in vulnerable populations such as older adults. This study evaluated the durability and dynamics of immune responses following booster vaccination(s) in.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

  • Avila-Nieto, Carlos
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Amengual-Rigo, Pep
  • Ainsua-Enrich, Erola|||0000-0001-7901-5798
  • Brustolin, Marco|||0000-0002-3594-4488
  • Rodriguez de la Concepción, Maria Luisa|||0000-0002-6944-3462
  • Pedreño López, Núria|||0000-0001-6927-2301
  • Rodon, Jordi|||0000-0002-1032-9091
  • Urrea, Víctor|||0000-0002-2577-856X
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Ballana, Ester|||0000-0002-5215-7363
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • Pérez, Mònica
  • Roca, Núria
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Ortiz, Raquel|||0000-0002-6919-2026
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Lepore, Rosalba
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Valencia, Alfonso|||0000-0002-8937-6789
  • Blanco, Julià|||0000-0002-2225-0217
  • Guallar, Victor|||0000-0002-4580-1114
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B.1.351 variants). Furthermore, S-V987H immunized K18-hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B.1.351 or Omicron BQ1.1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development. In this study, the authors report a mutation that increases the production of recombinant SARS-CoV-2 Spike and exposure of the RBD. In animal models, a Spike-based vaccine containing the mutation induces strong immunogenicity, provides protection from disease and results in faster tissue viral clearance.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Production and Immunogenicity of FeLV Gag-Based VLPs Exposing a Stabilized FeLV Envelope Glycoprotein

  • Ortiz, Raquel|||0000-0002-6919-2026
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Pons-Grífols, Anna|||0000-0002-8402-3941
  • Trinité, Benjamin|||0000-0003-3809-042X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Rovirosa, Carla|||0000-0002-7111-0253
  • Urrea, Víctor|||0000-0002-2577-856X
  • Barreiro Vázquez, Antonio|||0000-0001-6095-5077
  • Gonzalez-Tendero, Anna
  • Rovira-Rigau, Maria
  • Cardona, Maria
  • Ferrer, Laura
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Aguilar-Gurrieri, Carmen|||0000-0002-5701-7650
  • Blanco, Julià|||0000-0002-2225-0217
The envelope glycoprotein (Env) of retroviruses, such as the Feline leukemia virus (FeLV), is the main target of neutralizing humoral response, and therefore, a promising vaccine candidate, despite its reported poor immunogenicity. The incorporation of mutations that stabilize analogous proteins from other viruses in their prefusion conformation (e.g., HIV Env, SARS-CoV-2 S, or RSV F glycoproteins) has improved their capability to induce neutralizing protective immune responses. Therefore, we have stabilized the FeLV Env protein following a strategy based on the incorporation of a disulfide bond and an Ile/Pro mutation (SOSIP) previously used to generate soluble HIV Env trimers. We have characterized this SOSIP-FeLV Env in its soluble form and as a transmembrane protein present at high density on the surface of FeLV Gag-based VLPs. Furthermore, we have tested its immunogenicity in DNA-immunization assays in C57BL/6 mice. Low anti-FeLV Env responses were detected in SOSIP-FeLV soluble protein-immunized animals; however, unexpectedly no responses were detected in the animals immunized with SOSIP-FeLV Gag-based VLPs. In contrast, high humoral response against FeLV Gag was observed in the animals immunized with control Gag VLPs lacking SOSIP-FeLV Env, while this response was significantly impaired when the VLPs incorporated SOSIP-FeLV Env. Our data suggest that FeLV Env can be stabilized as a soluble protein and can be expressed in high-density VLPs. However, when formulated as a DNA vaccine, SOSIP-FeLV Env remains poorly immunogenic, a limitation that must be overcome to develop an effective FeLV vaccine.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention

  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
The development of HIV prophylactic vaccines is facing an impasse, since all phase IIb/III clinical trials were halted in 2023 without demonstrating efficacy. Thus, the field is in need of developing novel immunogens and vaccination strategies that induce broadly neutralising antibodies together with potent Fc-dependent effector functions, as well as protective cross-reactive CD4 and CD8 T cell responses. Nucleic acid vaccines, particularly mRNA vaccines, have been one of the major groundbreaking advances in the current decade. Nucleic acid vaccines may help recalibrate the HIV vaccine field towards the use of delivery systems that allow the proper expression of immunogens as a sole antigen (i.e., membrane-bound trimeric envelope glycoproteins) or even to be displayed in a multiantigen platform that will be synthesised by the host. In this review, we will summarise how the multiple HIV vaccine strategies pursued in the last 40 years of HIV research have driven current vaccine development, which are the most relevant immunogens identified so far to induce balanced adaptive immune responses, and how they can benefit from the acceptance of nucleic acid vaccines in the market by reducing the limitations of previous delivery systems. The incorporation of nucleic acid vaccines into the current heterogeneous repertoire of vaccine platforms may represent an invaluable opportunity to reignite the fight against HIV.